-
COURSE trial shows importance of biomarker testing in COPD
While overall the trial was negative, Meilan King Han, MD, MS, and Sanjay Ramakrishnan, MBBS, PhD, said it demonstrated the promise of tezepelumab for patients with baseline blood eosinophil counts ≥ 150 cells/µL.
Recent News
-
OSA and the Alzheimer’s continuum
OSA is being increasingly recognized as a potential contributor to neurodegeneration, particularly in the preclinical stages of Alzheimer’s disease. As early intervention becomes a priority in Alzheimer’s prevention, sleep disorders are being investigated as modifiable risk factors.
-
CHEST to offer first-of-its-kind certification for APPs in critical care
For APPs in the critical care setting, this certification exam will be a valuable way to validate their knowledge and competence in the ICU.
-
Aspergillus in bronchiectasis: An expanding spectrum of disease and diagnostic challenge
Recent findings underscore the need to integrate Aspergillus serologies into routine bronchiectasis care and adopt a phenotype-driven, personalized approach to fungal surveillance and treatment.
-
In our navigational bronchoscopy ERA
The VERITAS trial is a turning point for interventional pulmonology, ushering in an era of high-quality comparative effectiveness trials poised to transform our approach to technology evaluation, implementation, and, ultimately, patient care.
-
Airway pressure release ventilation: Should it be used in the early stages of ARDS?
APRV has traditionally been viewed as a salvage therapy for patients with ARDS, but recent literature suggests that it can provide better overall lung recruitment with less sedation and more ventilator-free days.
-
CMS decision positively impacts the future of home ventilation coverage
CMS recently released a decision on coverage for noninvasive ventilation devices for patients with COPD, a process that CHEST has been closely involved in.
